A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT04657003
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tirzepatide — DRUGAdministered SC
- Placebo — OTHERAdministered SC
Study Details
This is a study of tirzepatide in participants with type 2 diabetes who have obesity or are overweight. The main purpose is to learn more about how tirzepatide affects body weight. The study will last 79 weeks (22 visits).
Key Dates
- Start date
- Mar 29, 2021
- Status verified
- Mar 2024
- Primary completion
- Mar 16, 2023
- Completion
- Apr 10, 2023
Study Design
- Enrollment
- 938 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 10 milligrams (mg) Tirzepatide10 mg Tirzepatide administered subcutaneously (SC) once weekly (QW)
- Experimental: 15 mg Tirzepatide15 mg Tirzepatide administered SC QW
- Placebo Comparator: PlaceboPlacebo administered SC QW
Primary Outcome Measure
Percent Change From Baseline in Body Weight [ Time Frame: Baseline, Week 72 ]
Locations (43)
Find similar trials in Birmingham, AL
By condition
By specialty
By research site
University of Alabama - Department of Nutrition Sciences· Birmingham, ALKLR Business Group, Inc. dba Arkansas Clinical Research· Little Rock, ARVelocity Clinical Research, Huntington Park· Huntington Park, CAVelocity Clinical Research, Westlake· Los Angeles, CACatalina Research Institute, LLC· Montclair, CAEncompass Clinical Research· Spring Valley, CA
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Physical and Behavioral Traits of Overweight and Obese AdultsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular SystemRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia
- New Heart Imaging Techniques to Evaluate Possible Heart DiseaseRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland